14 September 2022 | News
Antengene is conducting 4 clinical trials in Australia with the company's four drug candidates
Image credit: prnewswire
Antengene, a biopharmaceutical startup founded in China, recently unveiled a new office space situated in Melbourne, Australia's most sought-after central business district (CBD), taking another important step in the company's continued global expansion.
In March 2022, XPOVIO (selinexor) was approved by the Australia Therapeutic Goods Administration (TGA) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM) or triple-refractory R/R MM. In September 2022, XPOVIO was included into the Pharmaceutical Benefits Scheme (PBS) for the treatment of patients with penta-refractory R/R MM.
While making steady progress with the commercialization of Antengene's lead asset, XPOVIO, in Australia and the wider Asia Pacific region, the Australian team continued to grow at a rapid rate to a total of fifteen members in a variety of functions covering Commercial, Finance, Medical Affairs, Clinical and Business Development. The office will enable closer collaborations with teams in other APAC markets and provide the extra space needed to support the team's continued expansion.
At present, Antengene is conducting 4 clinical trials in Australia with the company's four drug candidates, including ATG-018, ATG-101, ATG-037, and ATG-017, exploring these novel agents in a range of solid tumors and hematological malignancies. It is worth noting that ATG-037 is the first oral available, small molecule CD73 inhibitor entering clinical development in China and the wider Asia Pacific region. ATG-101, the first PD-L1/4-1BB bispecific antibody approved to enter clinical stage in Australia, is currently being evaluated in clinical setting in Australia, China, and the US.